<DOC>
	<DOCNO>NCT01347190</DOCNO>
	<brief_summary>Study assess safety tolerability single dose study-drug administer Cystic Fibrosis ( CF ) patient .</brief_summary>
	<brief_title>Safety Tolerability Study Liquid Alpha1 Proteinase Inhibitor ( API ) Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Have confirm diagnosis CF : one clinical finding consistent CF least one following : 1 . Sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test OR 2 . A genotype two identifiable mutation consistent CF ( ∆F508 homozygous two allele know cause class I , II , III mutation ) Have FEV1 ≥30 % predict normal defined age , gender , height Oxygen saturation &lt; 90 % Changed treatment regimen within 2 week prior screen Antibiotics regimen change &lt; 4 week screen Persistent colonization Burkholderia cepacia Serum IgA &lt; 50 % low level normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>